Immunoassay (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1371-1381

  Benraad, Th J ^d   Geurts Moespot, J ^d   Grondahl Hansen J ^a   Schmitt, M ^b   Heuvel, J J T M ^d   De Witte, J H ^d   Foekens, J A ^c   Leake, R E ^d   Brunner N ^a   Sweep, C G J ^d  

^a FINSEN LABORATORY   (Denmark)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NONE

Author keywords

Breast cancer; ELISA; EORTC; Quality assurance; Standardisation; uPA

Indexed keywords

UROKINASE; TUMOR MARKER;

ARTICLE; ASSAY; BREAST CANCER; CANCER INVASION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MEASUREMENT; METASTASIS; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; TECHNIQUE; ANALYTICAL EQUIPMENT; BREAST TUMOR; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CYTOSOL; ENZYMOLOGY; STANDARD;

BREAST NEOPLASMS; CYTOSOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; QUALITY CONTROL; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030037120     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00118-9     Document Type: Article

References (28)

1. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer 1978, 41, 1170-1178.
2. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971, 34, 55-70.
3. Walt AJ, Singhakowinta A, Brooks SC, Cortez A. The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 1976, 80, 506-512.
4. Bishop HM, Blarney RW, Elston CW, Haybittle JL, Nicholson RI, Griffiths K. Relationship of oestrogen-receptor status to survival in breast cancer. Lancet 1979, 2, 283-284.
5. Jensen EV. Steroid receptors in breast cancer: historical perspective. Cancer 1980, 46, 2759-2761.
6. Lippman ME, Allegra JC. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980, 46, 2829-2834.
7. Foekens JA, Portengen H, Look MP, et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 1994, 70, 1217-1223.
8. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC workshop, held on 16-17 March 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980, 16, 1513-1515.
9. Wittliff JL, Brown AM, Fisher B. Establishment of uniformity in steroid receptor determination for protocol B-09 of the National Surgical Adjuvant Breast Project. In Sarfaty GA, Nash AR, Keightly DD, eds. Estrogen Receptor Assays in Breast Cancer. Laboratory Discrepancies and Quality Assurance. New York; Masson, 1981, 27-39.
10. Koenders A, Benraad ThJ. Standardization of steroid receptor analysis in breast cancer biopsies: EORTC receptor group. Recent Results Cancer Res 1984, 91, 129-135.
11. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985, 44, 139-266.
12. Liotta LA, Stetler-Stevenson WG. Tumour invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991, 51, 5054s-5059s.
13. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993, 73, 161-195.
14. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 1988, 62, 531-533.
15. Jänicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990, 4, 69-78.
16. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 predict poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995, 87, 751-756.
17. Ganesh S, Sier CF, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994, 54, 4065-4071.
18. Pedersen H, Brünner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994, 54, 4671-4675.
19. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 1994, 151, 16-20.
20. Jänicke F, Pache L, Schmitt M, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994, 54, 2527-2530.
21. Camiolo SM, Siuta MR, Madeja JM. Improved medium for extraction of plasminogen activator from tissue. Prep Bioch 1982, 12, 297-305.
22. Rosenquist C, Thorpe SM, Danø K, Grøndahl-Hansen J. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 1993, 28, 223-229.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1, 307-310.
24. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins H, Fennell JJ, Andreasen P. Urokinase plasminogen activator: a new and independent prognostic marker in breast cancer. Cancer Res 1990, 50, 6827-6829.
25. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992, 52, 6101-6105.
26. Spyratos F, Martin PM, Hacène K, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992, 84, 1266-1272.
27. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993, 53, 2513-2521.
28. Büessecker F, Reinartz J, Schirmer U, Kramer MD. Enzyme-linked immunosorbent assays for plasminogen activators. J Immunol Meth 1993, 162, 193-200.